![Martin Steiner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin Steiner
Chief Executive Officer at SYNIMMUNE GmbH
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Horst Rose | M | - |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future.
ImVision Therapeutics, Inc.
![]() ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | - |
Ludger Große-Hovest | M | - |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | - |
Steffen Aulwurm | M | - |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | 14 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Simon Jules Nebel | M | 58 |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | 5 years |
Alfred Scheidegger | M | 67 |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | - |
Myoung-Ok Kwon | M | 53 |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | - |
Rene Amstutz | M | - |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | - |
Kaspar von Meyenburg | M | - |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 6 | 75.00% |
Germany | 3 | 37.50% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Martin Steiner
- Personal Network